<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03236012</url>
  </required_header>
  <id_info>
    <org_study_id>OP150030</org_study_id>
    <secondary_id>OP150030</secondary_id>
    <nct_id>NCT03236012</nct_id>
  </id_info>
  <brief_title>Hyperhidrosis in Patients With Amputations</brief_title>
  <official_title>Hyperhidrosis of the Residual Limb in Patients With Amputations: Developing a Treatment Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colby Hansen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Veterans Affairs Medical Center Health Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will address a problem that has troubled Service members, Veterans, and
      civilians with amputations for decades, impacting satisfaction with prosthetic use, residual
      limb skin health, and negatively affecting quality of life. Prior research in this area has
      been limited and insufficient. We are confident that improving the evaluation and treatment
      of residual limb hyperhidrosis will reduce the secondary health consequences of amputation
      and will lead to improved quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2017</start_date>
  <completion_date type="Anticipated">October 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Aim 1 and Aim 3 are not masked, but Aim 2 will be masked to the participant and investigator.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hyperhidrosis Disease Severity Scale.</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Hyperhidrosis Disease Severity Scale measurement is based of 1-4 points. Score 1 is the lowest severity and score 4 would be the highest severity for sweating.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>Iodine Skin Test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The iodine-starch test can be useful in diagnosing hyperhidrosis and grading its severity if it can demonstrate discriminate validity -- to accurately test positive in patients with the condition, and test negative in patients without the condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aluminum Chloride Topical</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test the effectiveness of a prescription strength topical antiperspirant Aluminum Chloride 20 percent on hyperhidrosis of the residual limb.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Toxin Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test the effectiveness of Botulinum Toxin therapy in subjects who fail or do not tolerate Aluminum Chloride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Minor Iodine-Starch Test</intervention_name>
    <description>The iodine-starch test is a valid diagnostic tool of hyperhidrosis and can be useful for the identification of focal areas of sweating on a residual limb.</description>
    <arm_group_label>Iodine Skin Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aluminum Chloride</intervention_name>
    <description>Aluminum Chloride 20 percent once daily for twelve weeks.</description>
    <arm_group_label>Aluminum Chloride Topical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Maximum dose up to 500 units given one time</description>
    <arm_group_label>Botulinum Toxin Therapy</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated informed consent form.

          -  Stated willingness to comply with all study procedures and availability for the
             duration of the study.

          -  Male or female, age 18 or older

          -  Have a prosthetic device

          -  In good general health as evidenced by medical history

          -  If subject is currently using aluminum chloride it must be discontinued for at least
             one week prior to participation in the study

        Exclusion Criteria:

          -  Open sores or wounds on the residual limb

          -  Known sensitivity or allergy to iodine

          -  Known sensitivity or allergy to Aluminum Chloride

          -  Pregnancy or lactation

          -  Known absolute or relative contraindications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colby Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi Hansen</last_name>
    <phone>801-278-3598</phone>
    <email>heidi.hansen@hsc.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heidi Hansen</last_name>
      <phone>801-585-2373</phone>
      <email>heidi.hansen@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Colby Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George E. Wahlen Department of Veterans Affairs Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bradeigh Godfrey, DO</last_name>
      <phone>801-582-1565</phone>
      <phone_ext>1764</phone_ext>
      <email>Bradeigh.godfrey@va.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Colby Hansen</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Aluminum chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

